0001739410-24-000105.txt : 20240723 0001739410-24-000105.hdr.sgml : 20240723 20240723160638 ACCESSION NUMBER: 0001739410-24-000105 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240723 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240723 DATE AS OF CHANGE: 20240723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rallybio Corp CENTRAL INDEX KEY: 0001739410 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851083789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40693 FILM NUMBER: 241134522 BUSINESS ADDRESS: STREET 1: 234 CHURCH STREET STREET 2: SUITE 1020 CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203- 859-3820 MAIL ADDRESS: STREET 1: 234 CHURCH STREET STREET 2: SUITE 1020 CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Rallybio Holdings, LLC DATE OF NAME CHANGE: 20180502 8-K 1 rlyb-20240723.htm 8-K rlyb-20240723
0001739410false00017394102024-07-232024-07-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________
FORM 8-K
______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):July 23, 2024
______________________________________________________
RALLYBIO CORPORATION
(Exact name of Registrant as Specified in Its Charter)
______________________________________________________
Delaware001-4069385-1083789
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
234 Church Street, Suite 1020 New Haven, Connecticut
06510
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 203 859-3820
(Former Name or Former Address, if Changed Since Last Report)
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per shareRLYBNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 23, 2024, Martin Mackay, Ph.D., informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he will resign his Executive Chairman role and his employment with Rallybio, effective December 31, 2024. Following termination of his employment, Dr. Mackay will remain a director of Rallybio and serve as Chairman of the Board. No severance will be paid to Dr. Mackay in connection with his resignation of employment.

Rallybio and Dr. Mackay expect to enter into a Consulting Agreement on January 1, 2025. (the Consulting Agreement). The Consulting Agreement provides that Dr. Mackay will serve as a consultant to Rallybio from January 1, 2025 until January 1, 2026. The consulting period may be extended upon mutual agreement. The Consulting Agreement may be terminated by either Rallybio or Dr. Mackay with sixty days' advance notice at any time. During the consulting period, Dr. Mackay will be an independent contractor and receive a consulting fee of $18,750 per month during the initial consulting period. The consulting fee is payable in monthly installments in arrears. Dr. Mackay's equity awards will continue to vest in accordance with their existing terms due to his service as a director. The Consulting Agreement provides that in the event of a Change of Control (as defined in the Consulting Agreement), Dr. Mackay's equity awards that are outstanding as of December 31, 2024 will become immediately vested.

The foregoing description of the Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of such agreement. A copy of the Form of Consulting Agreement between Rallybio and Dr. Mackay, expected to be executed on January 1, 2025, is filed with this Form 8-K.

Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit No.Description
10.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RALLYBIO CORPORATION
Date:July 23, 2024By:/s/ Jonathan I. Lieber
Jonathan I. Lieber
Chief Financial Officer and Treasurer

EX-10.1 2 rlyb-2024723xex101.htm EX-10.1 Document




Exhibit 10.1

CONSULTING AGREEMENT


This CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of this ___ day of ___________, 2025 (the “Effective Date”) by and among Rallybio Corporation (“Rallybio”), a Delaware corporation, Rallybio, LLC (“Rallybio LLC”), a Delaware limited liability company, and Martin Mackay, Ph.D. (“Dr. Mackay”). Rallybio LLC is party to this Agreement solely for purposes of Section 1 hereof.

WITNESSETH

WHEREAS, Dr. Mackay is currently employed by Rallybio LLC as Executive Chairman of Rallybio and Rallybio LLC pursuant to that certain Second Amended and Restated Employment Agreement (the “Employment Agreement”), dated as of August 1, 2023, by and among Dr. Mackay, Rallybio and Rallybio LLC;

WHEREAS, Dr. Mackay wishes to resign and terminate his employment as Executive Chairman, effective December 31, 2024;

WHEREAS, the Board of Directors of Rallybio (the “Board”) has determined that Dr. Mackay will continue his service on the Board as Chairman of the Board following the termination of his employment as Executive Chairman;

WHEREAS, Rallybio desires to secure the services of Dr. Mackay as a consultant to Rallybio effective as of the Effective Date, and Dr. Mackay desires to perform such services; and

WHEREAS, Rallybio and Dr. Mackay desire to enter into this Agreement to set forth the terms of Dr. Mackay’s consulting relationship with Rallybio.

NOW THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is hereby agreed by the parties as follows:

1.Termination of Employment. Dr. Mackay hereby acknowledges that he has resigned from his employment as Executive Chairman effective December 31, 2024, and that Dr. Mackay’s employment as Executive Chairman ended effective December 31, 2024 (the “Employment Term Date”). Rallybio and Rallybio LLC hereby accept such resignation as of the Employment Term Date. Dr. Mackay will be paid his base salary for his employment through the Employment Term Date. Dr. Mackay hereby acknowledges that with the receipt of Dr. Mackay’s final paycheck, other than as provided for below with respect to his 2024 annual bonus, he will have received all compensation and benefits that were due to Dr. Mackay through the Employment Term Date as a result of services performed for Rallybio and Rallybio LLC as Executive Chairman pursuant to the Employment Agreement. Dr. Mackay will remain eligible to be paid an annual bonus with respect to 2024 based on actual performance as determined by the Board or the Compensation Committee of the Board, with any such bonus to be paid at the same time as bonuses are paid to active employees of the Company, but no later than March 15, 2025.






2.Consulting Services. Dr. Mackay agrees to provide consulting services to Rallybio and Rallybio’s affiliates, including advising on research and scientific matters, strategy and strategic initiatives, capital raising, and investor relations, and such other services as reasonably requested by the Chief Executive Officer of Rallybio from time to time (the “Services”). Dr. Mackay agrees to devote such amount of time as is mutually determined by him and Rallybio to be reasonably required for him to perform the Services and to make himself available to perform the Services. Dr. Mackay shall be available to perform the Services pursuant to this Agreement during regular business hours, or as otherwise agreed, and either on site or remotely.

3.Compensation and Reimbursement; Equity Awards.

a.In full consideration of the Services performed by Dr. Mackay hereunder, Rallybio shall pay Dr. Mackay a fee in the amount of $18,750 per month (the “Consulting Fee”), pro-rated for partial months, which amount shall be paid not later than thirty (30) days after the end of the applicable calendar month. Rallybio shall reimburse Dr. Mackay for reasonable and customary out-of-pocket travel, hotel and other business expenses incurred at the request of Rallybio (the “Expenses”), subject to Rallybio’s expense reimbursement policies.

b.Any outstanding and unvested equity awards with a grant date on or prior to December 31, 2024, the vesting of which is based only on the passage of time, held by Dr. Mackay as of a Change in Control shall vest in full upon the consummation of the Change in Control, subject to Dr. Mackay remaining in a service relationship with Rallybio or its subsidiaries (for the avoidance of doubt, including as a consultant hereunder) through the date of such Change in Control.


i.As used herein, “Change in Control” shall mean the consummation of (1) the sale of all or substantially all of the assets of Rallybio on a consolidated basis to an unrelated individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) (a “Person”); (2) a merger, reorganization or consolidation pursuant to which the holders of Rallybio’s outstanding voting securities immediately prior to such transaction do not own more than fifty percent (50%) of the outstanding voting securities of the surviving or resulting entity (or its ultimate parent, if applicable); (3) the acquisition of more than fifty percent (50%) of the outstanding voting securities of Rallybio in a single transaction or a series of related transactions by any Person; or (4) the complete dissolution or liquidation of Rallybio; provided, , that Rallybio’s initial public offering, any subsequent public offering or anther capital raising event, a merger effected solely to change Rallybio’s domicile or any acquisition by Rallybio or any employee benefit plan (or related trust) sponsored or maintained by Rallybio or any of its subsidiaries or affiliates shall not constitute a “Change in Control”.


4.Duration. The period of this Agreement (the “Consulting Period”) will commence on the Effective Date and will terminate on the one-year anniversary of the Effective Date, unless





the Consulting Period is extended by mutual agreement of Dr. Mackay and the Chief Executive Officer of Rallybio and approved by the Board, or is earlier terminated as provided herein.

5.Termination of this Agreement. Dr. Mackay may terminate this Agreement upon sixty (60) days prior written notice to Rallybio. Rallybio may terminate this Agreement upon sixty (60) days prior written notice to Dr. Mackay. In the event of such termination by Rallybio, Dr. Mackay shall be entitled to payment of any earned but unpaid Consulting Fee through the date of termination and reimbursement of Expenses properly incurred prior to the date of termination.

6.Continuing Obligations. Dr. Mackay acknowledges and agrees that he remains bound by his obligations under (a) the Confidential Information and Invention Assignment Agreement, dated January 5, 2018, which Dr. Mackay signed in connection with his employment, including without limitation the obligations under Sections 2 - 8 thereof, and (b) the Employment Agreement, including without limitation the obligations under Sections 11 and 12 thereof; in each case that survive the termination of Dr. Mackay’s employment in accordance with the respective terms thereof (collectively, the “Continuing Obligations”).

7.Representations and Warranties. Dr. Mackay represents and warrants that: (a) Dr. Mackay has the full right and authority to enter into this Agreement and perform Dr. Mackay’s obligations hereunder; and (b) Dr. Mackay’s execution, delivery and performance of this Agreement will not result in any breach of or constitute a default under or require any consent under, any agreement to which Dr. Mackay is a party or is otherwise bound.

8.Independent Contractor. Following the Employment Term Date, Dr. Mackay’s relationship with Rallybio shall be that of an independent contractor, and Dr. Mackay shall not be an employee of Rallybio for any purpose whatsoever. Unless otherwise agreed by the parties herein or otherwise in writing, Dr. Mackay shall not be entitled to participate in any fringe benefits or privileges given or extended by Rallybio to its officers and employees, including medical benefits, retirement plans or equity incentive plans. Dr. Mackay shall be responsible for the payment of all federal, state and local taxes, including withholding taxes, and, at the request of Rallybio, Dr. Mackay shall provide to Rallybio evidence that all of such payments have been made.

9.Further Assurances. Dr. Mackay and Rallybio will execute all documents and take all such actions to effect the transactions contemplated in this Agreement, as reasonably requested by the other and at the requesting party’s expense.

10.Notices. Any notice or other communication hereunder shall be in writing, shall be given either by email, in person or by certified or registered mail (return receipt requested), addressed to the party to be notified at its address first set forth herein, and shall be deemed sufficiently given as of the third day thereafter. Either party may, by written notice to the other, change its address for receiving such notices and communications.

11.Assignability. This Agreement shall inure to the benefit of any assignee of Rallybio, and Dr. Mackay specifically agrees on demand to execute any and all necessary documents in connection therewith. Dr. Mackay may not assign this Agreement or delegate the performance of his obligations hereunder without the express written consent of Rallybio. Rallybio may assign any of its rights or obligations to a third party hereunder without





consent of Dr. Mackay. Any attempted assignment or delegation in contravention of this Section 11 shall be null and void ab initio.

12.Governing Law; Venue. The provisions of Section 19 of the Employment Agreement shall apply to this Agreement mutatis mutandis.

13.Word Meanings. The words “herein,” “hereinafter,” “hereof” and “hereunder” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. The singular shall include the plural and the masculine gender shall include the feminine and neuter, and vice versa, unless the context otherwise requires. The words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation” and shall not be construed to limit any general statement that it follows to the special or similar items or matters immediately following it.

14.Entire Agreement. This Agreement sets forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and understandings, written or oral, express or implied, with respect to the subject matter hereof, provided that nothing herein will limit or supersede the Continuing Obligations. As of the Effective Date, the Employment Agreement will terminate; provided that the provisions thereof that are intended to survive its termination, including, but not limited to the Continuing Obligations, will remain in effect in accordance with their terms.

15.Severability. Dr. Mackay hereby agrees that each provision herein shall be treated as a separate and independent clause, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of this Agreement. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it or them so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear.

16.Survival. Provisions intended to survive termination of this Agreement shall survive termination or expiration of this Agreement.

17.Counterparts; Facsimile or Electronic Execution and Delivery. This Agreement may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. Facsimile or electronic execution or delivery of this Agreement shall constitute legal, valid and binding execution or delivery for all purposes.

[Signature page follows.]













IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto, as of the Effective Date.

RALLYBIO CORPORATION


By:
Name:
Title:

Date: ____________________




RALLYBIO, LLC


By:
Name:
Title:

Date: ____________________




MARTIN MACKAY:



Martin Mackay, Ph.D.

Date: ______________________

Address: ____________________
____________________
____________________


EX-101.SCH 3 rlyb-20240723.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rlyb-20240723_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Ex Transition Period Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Written Communications Written Communications Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rlyb-20240723_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 23, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 23, 2024
Entity Registrant Name RALLYBIO CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-40693
Entity Tax Identification Number 85-1083789
Entity Address, Address Line One 234 Church Street,
Entity Address, Address Line Two Suite 1020
Entity Address, City or Town New Haven,
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06510
City Area Code 203
Local Phone Number 859-3820
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol RLYB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Central Index Key 0001739410
Amendment Flag false
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://rallybio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rlyb-20240723.htm rlyb-20240723.xsd rlyb-20240723_lab.xml rlyb-20240723_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rlyb-20240723.htm": { "nsprefix": "rlyb", "nsuri": "http://rallybio.com/20240723", "dts": { "inline": { "local": [ "rlyb-20240723.htm" ] }, "schema": { "local": [ "rlyb-20240723.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "rlyb-20240723_lab.xml" ] }, "presentationLink": { "local": [ "rlyb-20240723_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://rallybio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rlyb-20240723.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rlyb-20240723.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://rallybio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001739410-24-000105-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739410-24-000105-xbrl.zip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end XML 16 rlyb-20240723_htm.xml IDEA: XBRL DOCUMENT 0001739410 2024-07-23 2024-07-23 0001739410 false 8-K 2024-07-23 RALLYBIO CORPORATION DE 001-40693 85-1083789 234 Church Street, Suite 1020 New Haven, CT 06510 203 859-3820 false false false false Common Stock, par value $0.0001 per share RLYB NASDAQ true false